In this episode, Dr Ashish Sharma and guest faculty Professor Francesco Bandello take a deep dive into the biosimilar development, testing and approval processes, exploring similarities and differences across Europe and the US. In this discussion, Dr Sharma and Professor Bandello explore barriers to development and approval of biosimilars, comparing and contrasting key regulatory considerations and requirements, including aspects such as interchangeability and reference products. They also explore how the strong track record of biosimilars in Europe and an understanding of the regulatory process can help healthcare professionals to improve their knowledge and trust in biosimilars, enabling patients to have access to these cost-effective treatment options in practice.

Join ophthalmologist Dr Ashish Sharma and guest faculty Dr Anat Loewenstein, as they explore key evidence behind regulatory approval of the first anti-VEGF biosimilar (ranibizumab-nuna) in the US and Europe. Listen to a brief overview of this biosimilar’s efficacy and safety profile compared to reference ranibizumab in patients with retinal disease and hear expert insights about what these findings mean in practice for retina specialists and ophthalmologists weighing up treatment options for their patients.

In this first episode of the Advances in Ophthalmology Podcast Series, join ophthalmologist Dr Ashish Sharma and guest faculty Dr Nancy Holekamp to explore how anti-vascular endothelial growth factor (anti-VEGF) biosimilars may help to address unmet needs in treatment of retinal disease, including earlier access to treatment. As a potentially more cost-effective solution, and how they may help to improve patient access to care and early treatment.